Forminard Elizabeth, Executive VP and General Counsel at Johnson & Johnson (JNJ), has demonstrated a clear net selling bias in her insider transactions, with $5.48 million in total sales outweighing $2.49 million in purchases across 24 filings. Her activity has been exclusively concentrated in JNJ shares, with no trades in other securities. The transactions reveal a pattern of periodic stock sales, often paired with smaller acquisitions, likely tied to equity compensation. Notably, on February 13, 2026, she disposed of shares worth $1.71 million—her largest single transaction—followed by additional sales totaling $252,214 on February 15, 2026. Earlier transactions show similar activity, including a $1.48 million sale on February 5, 2026, and a $1.70 million disposition on August 29, 2025, each accompanied by smaller purchases.
While some filings show acquisitions—such as a $372,526 purchase on February 13, 2024, and a $162,752 buy on February 12, 2024—these were substantially outweighed by concurrent sales. Many filings reflect derivative transactions (code "M") with no immediate monetary value, likely involving option exercises or vesting events. The absence of recent buys suggests a continued divestment trend, though the transactions appear structured rather than discretionary, possibly tied to scheduled equity compensation events. Over the observed period, Forminard's trading leans decisively toward reducing her JNJ position, with sales consistently exceeding purchases in both frequency and dollar value.
AI-assisted summary